MK-677
mk677
research_page
MK-677 Peptide Research
MK-677 Peptide Research
Reviewing ibutamoren as an oral ghrelin receptor agonist for GH-axis signaling
MK-677 is an oral ghrelin receptor agonist studied for growth hormone secretion, IGF-1 elevation, sleep effects, and body-composition changes.
MK-677 is a non-peptide ghrelin receptor agonist studied for GH and IGF-1 stimulation.
Some of the biggest claims about MK-677 move faster than the evidence. This page focuses on what the published research actually shows.
MK-677, also known as ibutamoren, is an orally active ghrelin receptor agonist developed to stimulate endogenous growth hormone release without direct GH injection. It has real human clinical data, but it is not FDA approved.
It activates the ghrelin receptor, increasing pulsatile growth hormone secretion and raising circulating IGF-1. This links it to endocrine, sleep, and body-composition research rather than direct GH replacement.
Clinical interest centers on hormone optimization, body recomposition, sleep architecture, aging-related catabolism, and GH-axis support. It is usually discussed as an oral alternative to injectable secretagogues, though that does not make it clinically interchangeable with approved therapies.
Human trials show that MK-677 can increase GH and IGF-1, improve sleep measures, and increase fat-free mass in some populations. The evidence is materially stronger than for many gray-market peptides, but still much weaker than for approved endocrine or obesity drugs.
Relevant concerns include appetite increase, edema, insulin sensitivity changes, elevated glucose in some users, and overstatement of body-composition effects. It should not be framed as a benign shortcut.
MK-677 is one of the better-studied GH-axis compounds outside approved therapy, but it is still not an approved standard of care.
Moderate
Clinical
Not Approved
ghrelin receptor agonist
gh-axis|hormone-optimization|body-recomposition
informational
hormone-optimization
muscle-growth
sleep
ipamorelin|sermorelin|cjc-1295-ipamorelin|hexarelin|somatropin
performance-stack|gh-optimization-stack|ghrelin-drive-stack
hormone-optimization|muscle-growth|sleep|longevity
mk-677-vs-ipamorelin|mk-677-vs-sermorelin
study121|study122|study123|study124|study125|study141|study146
MK-677 peptide research
MK-677 studies|ibutamoren research|MK-677 vs ipamorelin
MK-677 Research: Mechanism, Studies, and Evidence
Evidence-based review of MK-677, including ghrelin-receptor signaling, GH/IGF-1 effects, sleep findings, and clinical limitations.
MK-677 Research: Mechanism, Studies, and Evidence
Evidence-based review of MK-677, including ghrelin-receptor signaling, GH/IGF-1 effects, sleep findings, and clinical limitations.
What is MK-677?
MK-677 is an oral ghrelin receptor agonist studied for increasing endogenous growth hormone and IGF-1 levels.
Is MK-677 the same as growth hormone?
No. MK-677 stimulates the body to release more GH, while somatropin is direct recombinant human growth hormone.
What is MK-677?
MK-677 is an oral ghrelin receptor agonist studied for GH and IGF-1 stimulation.
Useful GH-axis research compound with real human data, but not an approved medical standard.
Oral GH secretagogue|Human clinical data exists|Not FDA approved
Peptiders Research Team
Peptiders Clinical Review Board
MedicalWebPage
Drug
Endocrine|Metabolic
/images/mk-677.jpg
MK-677 peptide research overview
published